Distribution of tumor subtypes in bilateral breast cancer: Comparison between synchronous and metachronous cancer

2020 ◽  
Author(s):  
Haeyoung Kim ◽  
Hyebin Lee ◽  
Doo Ho Choi ◽  
Won Park ◽  
Won Kyung Cho ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer ◽  
Metachronous Cancer ◽  
Tumor Subtypes

Incidence and Prognosis of Synchronous and Metachronous Bilateral Breast Cancer

2007 ◽  
Vol 25 (27) ◽  
pp. 4210-4216 ◽  
Author(s):  
Mikael Hartman ◽  
Kamila Czene ◽  
Marie Reilly ◽  
Jan Adolfsson ◽  
Jonas Bergh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Bilateral Breast Cancer ◽  
Metachronous Cancer ◽  
Unilateral Breast Cancer ◽  
Dual Effect ◽  
Prognostic Features ◽  
Incidence Trends ◽  
Incidence And Mortality ◽  
Synchronous Breast Cancer

Purpose Because the incidence of breast cancer is increasing and prognosis is improving, a growing number of women are at risk of developing bilateral disease. Little is known, however, about incidence trends and prognostic features of bilateral breast cancer. Patients and Methods Among 123,757 women with a primary breast cancer diagnosed in Sweden from 1970 to 2000, a total of 6,550 developed bilateral breast cancer. We separated synchronous (diagnosed within 3 months after a first breast cancer) and metachronous bilateral cancer, and analyzed incidence and mortality rates of breast cancer using Poisson regression models. Results The incidence of synchronous breast cancer increased by age and by 40% during the 1970s, whereas the incidence of metachronous cancer decreased by age and by approximately 30% since the early 1980s, most likely due to increasing use of adjuvant therapy. Women who developed bilateral cancer within 5 years and at age younger than 50 years were 3.9 times (95% CI, 3.5 to 4.5) more likely to die as a result of breast cancer than women with unilateral cancer. Women with a bilateral cancer diagnosed more than 10 years after the first cancer had a prognosis similar to that of a unilateral breast cancer. Adjuvant chemotherapy of primary cancer is a predictor of poor survival after diagnosis of early metachronous cancers. Conclusion We found profound differences in the incidence trends and prognostic outlook between synchronous and metachronous bilateral breast cancer diagnosed at different ages. Adjuvant chemotherapy therapy has a dual effect on metachronous cancer: it reduces the risk, while at the same time it seems to worsen the prognosis.

Morphea-like Carcinoma En Cuirasse Revealing a Bilateral Breast Cancer

2021 ◽  
Author(s):  
Mouna Ben Hamouda ◽  
Amina Aounallah ◽  
Taghrid Tlili ◽  
Zied Kenani ◽  
Rima Gammoudi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer

scholarly journals Patient-private disease evolution and heterogeneity in bilateral breast cancer

2016 ◽  
Vol 27 ◽  
pp. vi54
Author(s):  
E. Fountzila ◽  
V. Kotoula ◽  
F. Zagouri ◽  
E. Giannoulatou ◽  
G. Kouvatseas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer ◽  
Disease Evolution

Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male

2001 ◽  
Vol 24 (6) ◽  
pp. 454-459 ◽  
Author(s):  
Franco Forloni ◽  
M. Giovilli ◽  
C. Pecis ◽  
E. Bortolani ◽  
A. Preziosi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer ◽  
Pituitary Prolactin

Searching for susceptibility alleles: Emphasis on bilateral breast cancer

2007 ◽  
Vol 121 (4) ◽  
pp. 921-923 ◽  
Author(s):  
Evgeny N. Imyanitov ◽  
Cees J. Cornelisse ◽  
Peter Devilee
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer

scholarly journals Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

2010 ◽  
Vol 28 (18) ◽  
pp. 2966-2973 ◽  
Author(s):  
Marco Colleoni ◽  
Bernard F. Cole ◽  
Giuseppe Viale ◽  
Meredith M. Regan ◽  
Karen N. Price ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Triple Negative ◽  
Alkylating Agents ◽  
Growth Factor Receptor ◽  
Breast Cancers ◽  
Her2 Positive ◽  
Node Negative ◽  
Tumor Subtypes ◽  
Node Negative Breast Cancer

Purpose Retrospective studies suggest that primary breast cancers lacking estrogen receptor (ER) and progesterone receptor (PR) and not overexpressing human epidermal growth factor receptor 2 (HER2; triple-negative tumors) are particularly sensitive to DNA-damaging chemotherapy with alkylating agents. Patients and Methods Patients enrolled in International Breast Cancer Study Group Trials VIII and IX with node-negative, operable breast cancer and centrally assessed ER, PR, and HER2 were included (n = 2,257). The trials compared three or six courses of adjuvant classical cyclophosphamide, methotrexate, and fluorouracil (CMF) with or without endocrine therapy versus endocrine therapy alone. We explored patterns of recurrence by treatment according to three immunohistochemically defined tumor subtypes: triple negative, HER2 positive and endocrine receptor absent, and endocrine receptor present. Results Patients with triple-negative tumors (303 patients; 13%) were significantly more likely to have tumors > 2 cm and grade 3 compared with those in the HER2-positive, endocrine receptor–absent, and endocrine receptor–present subtypes. No clear chemotherapy benefit was observed in endocrine receptor–present disease (hazard ratio [HR], 0.90; 95% CI, 0.74 to 1.11). A statistically significantly greater benefit for chemotherapy versus no chemotherapy was observed in triple-negative breast cancer (HR, 0.46; 95% CI, 0.29 to 0.73; interaction P = .009 v endocrine receptor–present disease). The magnitude of the chemotherapy effect was lower in HER2-positive endocrine receptor–absent disease (HR, 0.58; 95% CI, 0.29 to 1.17; interaction P = .24 v endocrine receptor–present disease). Conclusion The magnitude of benefit of CMF chemotherapy is largest in patients with triple-negative, node-negative breast cancer.

Estrogen and Progesterone Receptor Content in Bilateral Breast Cancer

1995 ◽  
Vol 191 (1) ◽  
pp. 16-24 ◽  
Author(s):  
M. Branković-Magić ◽  
D. Nikolić-Vukosavljević ◽  
Z. Nešković- Konstantinović ◽  
K. Kanjer ◽  
I. Spužić
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Bilateral Breast Cancer ◽  
Estrogen And Progesterone Receptor
Sign in / Sign up

Export Citation Format

Share Document